StockpollyBeta
Get App
Popularity #1,593
PEN · NYSE · Medical - Devices

Penumbra (PEN)

Builds clot-removal, embolization, and vascular-access devices for neurovascular and peripheral procedures.

$319.39
After hours0.00 (0.00%)
At close$319.39(+0.19%)

  1. Reasons to Retain Penumbra Stock in Your Portfolio for Now

    Zacks Investment Research

  2. Connor Clark & Lunn Investment Management Ltd. Buys New Position in Penumbra, Inc. $PEN

    Defense WorldOwnership

  3. Penumbra, Inc. Reports Second Quarter 2026 Financial Results

    PRNewsWire

  4. Bank of Nova Scotia Acquires 210,402 Shares of Penumbra, Inc. $PEN

    Defense World

  5. California Public Employees Retirement System Increases Position in Penumbra, Inc. $PEN

    Defense World

  6. THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

    GuruFocus

  7. THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

    PRNewsWire

  8. Penumbra, Inc. $PEN Shares Sold by Bank of New York Mellon Corp

    Defense World

  9. First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke

    PRNewsWire

  10. Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?

    Zacks Investment Research

  11. Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT

    PRNewsWire

  12. Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke

    PRNewsWire

  13. Why Is Penumbra (PEN) Down 1.2% Since Last Earnings Report?

    Zacks Investment Research

  14. Penumbra (PEN) Misses Q1 Earnings Estimates

    Zacks Investment Research

  15. 3 Reasons Why Penumbra (PEN) Is a Great Growth Stock

    Zacks Investment Research

  16. Here's Why Penumbra (PEN) is a Strong Growth Stock

    Zacks Investment Research

  17. New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients

    PRNewsWire

  18. 3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN)

    Zacks Investment Research

  19. Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN

    Business Wire

  20. Penumbra (NYSE:PEN) Director Harpreet Grewal Sells 100 Shares

    Defense World